Concurrent Targeting of GSK3 and MEK as a Therapeutic Strategy to Treat Pancreatic Ductal Adenocarcinoma

Scientists identified Glycogen synthase kinase 3 (GSK3) as a therapeutic target through a whole-body genetic screening utilizing a ‘4-hit’ Drosophila model mimicking the PDAC genotype.